Full Press Release Details
Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C..
ALT
Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
Key Takeaway: Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight